Japanese drugmaker Sosei Group (TSE Mothers Index: 4565) has announced that Andrew Oakley is to become its chief financial officer (CFO).
Working from Sosei’s Tokyo offices, he will take over from Hidetoshi Torami, who has resigned from the company for personal reasons.
Mr Oakley’s arrival comes nine months after the appointment of Peter Bains as chief executive of the company, which is focused on the discovery and development of innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease and other indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze